# An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

> **NCT04076059** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Astellas Pharma China, Inc.** · enrollment: 180 (actual)

## Conditions studied

- Metastatic Hormone Sensitive Prostate Cancer

## Interventions

- **DRUG:** Enzalutamide
- **DRUG:** Placebo
- **DRUG:** Androgen deprivation therapy (ADT)

## Key facts

- **NCT ID:** NCT04076059
- **Lead sponsor:** Astellas Pharma China, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-09-11
- **Primary completion:** 2022-11-18
- **Final completion:** 2028-12-31
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04076059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04076059, "An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04076059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*